Skip to main content

Increase Your Chances Of Pregnancy


miRNA-based Receptivity Analysis

MIRATM helps to identify your best time for embryo transfer more reliably.

What Is Endometrial Receptivity?

One of the key factors that impact the success rate of IVF treatment is implantation, which is a complex process involving the quality of embryos, the thickness of uterine lining and the receptivity of endometrium. In order for a healthy embryo to attach successfully, the endometrium must be receptive.

Around day 19 and day 21 of a cycle, cells from the uterus lining undergo specific changes to facilitate embryo attachment. This period of receptivity is very brief (about one to two days) and every woman has a different window of implantation. Outside this window, the embryo is unable to attach to the uterus.

You can increase your chances of pregnancy by transferring your embryos during your window of implantation.

Inadequate endometrial receptivity contributes to one third of implantation failures.1

MIRATM Proven Performance2


Prediction rate of receptivity at 99% with a successful implantation rate of more than 70%.


Less than 1% resampling rate, significantly lower than the 15% resampling rate of competing products.

Who should take this test?

Any women who:

  • have had two or more miscarriages;
  • have scheduled an IVF treatment;
  • have had recurrent implantation failures but with good quality embryos;
  • have very few embryos available for transfer and need to maximise their chances for each embryo.

Why is MIRATM Better?

Unlike other tests that examine mRNA, MIRATM is a miRNA-based technology that enables the analysis of a panel of miRNA biomarkers. Compared to mRNA-based analysis, miRNA-based test is:3,4,5

More Stable

Lower test failure rate

More Sensitive

Lesser sampling tissue required

More Precise

More reliable diagnostic outcome

Less Chance of Repeat Biopsy

Avoid unnecessary repeat biopsy

How Is The Test Done?

A small sample of a woman’s endometrial lining is required for analysis. This sample can be quickly and easily obtained through an outpatient procedure performed by your gynaecologist. Some patients may experience mild discomfort and cramping pain during or after the procedure. The pain is described to be the same as a period.

Talk To Your Obstetrician Or Gynaecologist About MIRATM Today.

1.Altmae S, Koel M, Vosa U, et al. Meta-signature of human endometrial receptivity: a meta-analysis and validation study of transcriptomic biomarkers. Scientific Reports. 2017;7(1):1-15.
2.Based on GGA Corporation’s internal data.
3.Minoura K, Sawada Y, Valer M, Wang H. MicroRNA profiling is more stable than messenger RNA against RNA degradation. AACR. 2008;68(9):5029.
4.Jung M, Schaefer A, Steiner I, Kempkensteffen C, Stephan C, Erbersdobler A, et al. Robust microRNA stability in degraded RNA preparations from human tissue and cell samples. Clin Chem. 2010;56(6):998–1006.
5.Aryani A, Denecke B. In vitro application of ribonucleases: comparison of the effects on mRNA and miRNA stability. BMC Research Notes. 2015;8:164.

MIRATM is a service offered for human in vitro fertilization (IVF) clinics. MIRATM can help to determine the endometrial receptivity in order to identify the best time for implantation of an embryo, or often referred to as the window of implantation (WOI). The optimal time for embryo transfer varies among individuals. The implantation window can be compared to varying cropping seasons, which can be shorted and/or delayed depending on the location. By determining the best timing for implantation, a correct diagnosis can help increase the chances of implantation success, thus increasing the possibility of a successful in vitro fertilization treatment cycle. MIRATM is based on the expression of miRNA biomarkers, run on PanelChip® Analysis System.

MIRATM is brought to you by PT. Cordlife Persada in partnership with Taiwan-based laboratory – Genetics Generation Advancement Corp. (GGA).